C4 Therapeutics CFO Kendra Adams Receives 6,250 RSU Shares

What Happened

• Kendra Adams, Chief Financial Officer of C4 Therapeutics (CCCC), had 6,250 shares issued to her upon vesting/settlement of previously granted RSUs (reported as an exercise/conversion). Of those, 2,775 shares were withheld by the company to satisfy tax withholding obligations, representing a withholding value of $9,407 (2,775 shares × $3.39). Net shares delivered to Adams after withholding: 3,475 shares.

Key Details

• Transaction date: September 18, 2026 (reported on Form 4 filed Sep 21, 2026).
• Acquisition: 6,250 shares acquired upon RSU vesting (code M) at $0.00 per share.
• Withholding: 2,775 shares withheld for taxes (code F) at $3.39 per share; withholding value $9,407. This withholding is not a sale by the reporting person.
• Footnotes: The RSU grant that vested was originally reported by the reporting person on September 19, 2023 (per filing footnote).
• Shares owned after transaction: Not specified in the Form 4 filing.

Context

• This transaction reflects RSU vesting and a routine tax-withholding settlement, not an open-market purchase or discretionary sale. The withholding is a company action to meet tax obligations and should not be interpreted as an independent sale by the insider.